Clene to Present at Upcoming May Conferences

Rhea-AI Summary

Clene (Nasdaq: CLNN) will participate in two investor events in early May 2026: a virtual Emerging Growth Conference presentation on May 6, 2026 at 3:25 p.m. ET and one-on-one meetings at the D. Boral Capital Global Conference on May 7, 2026 at The Plaza Hotel, New York.

Presentation access is available via a webcast link and investor meetings are scheduled as 1x1 sessions.

News Market Reaction – CLNN

-18.67%

29 alerts

-18.67% Session close to close

+2.6% Peak Tracked

-10.4% Trough Tracked

$95.29M Market Cap

0.7x Rel. Volume

In the May 5 session, CLNN declined 18.67%, reflecting a significant negative market reaction. Argus tracked a peak move of +2.6% during that session. Argus tracked a trough of -10.4% from its starting point during tracking. Our momentum scanner triggered 29 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -18.7% in the session following this news. A negative reaction despite seemingly r...

Analysis

The stock dropped -18.7% in the session following this news. A negative reaction despite seemingly routine conference news would fit a pattern where shares had already advanced on prior regulatory and financing catalysts. With the price previously up 31.76% and trading above the $6.22 200-day MA, profit-taking could dominate around low-impact updates. Existing overhang from prior financings and a resale shelf for note-related shares could further amplify downside once short-term momentum cooled.

Key Figures

Emerging Growth date: May 6, 2026 Presentation time: 3:25 p.m. ET D. Boral Capital date: May 7, 2026

3 metrics

Emerging Growth date May 6, 2026 Investor conference presentation date

Presentation time 3:25 p.m. ET Emerging Growth Conference virtual presentation

D. Boral Capital date May 7, 2026 In-person investor meetings at The Plaza Hotel

Historical Context

5 past events · Latest: May 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	Regulatory feedback	Positive	+31.8%	FDA minutes supporting potential accelerated approval NDA pathway for CNM-Au8 in ALS.
Mar 12	Earnings and financing	Positive	+6.1%	Full-year 2025 results, narrowed net loss, and oversubscribed registered direct offering.
Feb 24	Pipeline catalysts update	Positive	+9.8%	Outlined 2026 CNM-Au8 catalysts, including accelerated NDA plans and Phase 3 RESTORE-ALS trial.
Feb 19	Investor conference	Neutral	+4.7%	Announcement of a virtual corporate update at the Emerging Growth Conference.
Jan 16	Investor conference	Neutral	-1.2%	Plan to present a corporate update at the January Emerging Growth Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent price reactions have generally aligned with positive regulatory and financing milestones, with strong upside moves on ALS regulatory updates and more modest reactions to conference appearances.

Recent Company History

Over the last few months, Clene has reported several key developments. On May 4, 2026, the FDA indicated Clene’s data may support an accelerated approval NDA for CNM-Au8 in ALS, with an NDA targeted for Q3 2026 and a Phase 3 study in Q1 2027, prompting a 31.76% move. Earlier, full-year 2025 results and financing on March 12, 2026 coincided with a 6.09% gain, while a February stockholder letter outlining 2026 catalysts saw a 9.8% rise. Prior conference announcements produced smaller, mixed reactions.

Key Terms

amyotrophic lateral sclerosis, multiple sclerosis

2 terms

amyotrophic lateral sclerosis medical

"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

multiple sclerosis medical

"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"

A chronic neurological disease in which the immune system damages the protective coating (like insulation on electrical wires) around nerves, disrupting signals between the brain and body and causing symptoms such as numbness, weakness, vision problems, fatigue and mobility issues. It matters to investors because the unpredictability and long-term nature of the condition drive ongoing demand for treatments, influence the value of companies developing therapies, affect healthcare costs and shape regulatory and reimbursement decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in May.

Emerging Growth Conference
Date: May 6, 2026
Time of Presentation: 3:25 p.m. ET
Format: Virtual Presentation
Presentation Link: https://goto.webcasts.com/starthere.jsp?ei=1755070&tp_key=280dc3ffe3&sti=clnn

D. Boral Capital Global Conference
Date: May 7, 2026
Location: The Plaza Hotel, New York, New York
Format: 1x1 meetings

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact: Kevin Gardner, LifeSci Advisors; kgardner@lifesciadvisors.com; (617) 283-2856

Media Contact: Caroline Wagner, Forbes Tate Partners; CWagner@forbes-tate.com; (267) 294-6563 

FAQ

When will Clene (CLNN) present at the Emerging Growth Conference in May 2026?

Clene will present virtually on May 6, 2026 at 3:25 p.m. ET. According to the company, the session is a virtual presentation with a provided webcast link for investors to watch the presentation live or via replay.

How can investors access Clene's (CLNN) Emerging Growth Conference presentation on May 6, 2026?

Investors can access the presentation via the company's webcast link. According to the company, the link is provided for the virtual presentation and should allow live viewing and potential replay through the event host's webcast portal.

Will Clene (CLNN) meet investors in person at the D. Boral Capital Global Conference on May 7, 2026?

Clene will hold one-on-one investor meetings at the D. Boral Capital Global Conference on May 7, 2026. According to the company, these are scheduled 1x1 meetings at The Plaza Hotel in New York to engage directly with investors.

What topics will Clene (CLNN) likely cover in its May 2026 investor presentations?

The company will discuss its clinical-stage programs in neurodegenerative diseases such as ALS and MS. According to the company, presentations and meetings will focus on its late clinical-stage development and strategic progress for its therapeutic candidates.

Is the Emerging Growth Conference presentation by Clene (CLNN) available for replay after May 6, 2026?

A replay is typically available through the webcast portal after the live presentation. According to the company, investors can use the provided webcast link to access on-demand replay if the event host posts it post-presentation.

Where and when will Clene (CLNN) participate in investor events during the first week of May 2026?

Clene will participate virtually at the Emerging Growth Conference on May 6, 2026 and hold in-person 1x1 meetings at the D. Boral Capital Global Conference on May 7, 2026. According to the company, the in-person meetings occur at The Plaza Hotel in New York.